Natural CapsulesQ4 FY26
Natural Capsules Q4 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹167Market Cap: ₹158 CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
- →Capsules Business:
- → - Gelatin capsules revenue forecast for FY27: ~Rs. 170 crores.
- → - HPMC capsules revenue expected to start second half of FY27, projected around Rs. 20 crores.
- → - Focus on optimizing utilization at Bangalore and Puducherry plants and shifting product mix towards regulated markets.
- →API Business:
- → - Domestic API sales expected ~Rs. 70 crores in FY27.
- → - Targeting Rs. 250 crore revenue from API in 2-3 years with additional capacity and clean rooms.
- → - Commercial API sales started in Q4 FY26; margins currently low but expected to improve with further certifications (WHO GMP by Q2 FY27, USFDA by Q3/Q4 FY27).
- →Fermbox Collaboration:
- → - Expected to enhance fermentation block utilization and create incremental revenue.
- →Overall:
- → - Consolidated revenue target for FY27: Rs. 274 crores.
- → - EBITDA expected to improve with better customer mix and regulatory approvals.
- → - Growth supported by new product lines, market expansions (Europe, US), and technology partnerships.
Margin guidance
- →EBITDA margins saw a COVID-driven surge up to ~20-22% during FY21-FY23 but have declined to ~12-13% currently as supply chain normalizes.
- →HPMC capsule margins (~18% EBITDA) are higher than gelatin (~12-13%), and scaling HPMC volumes is expected to improve overall margins by ~200 basis points.
- →FY27 revenue targets: Capsule sales Rs. 190 crores (Gelatin Rs.170 cr, HPMC Rs.20 cr), API Rs.70 cr, contract manufacturing Rs.14 cr.
- →API segment currently low margin or negative EBITDA but expected to improve with regulatory approvals and better customer base; fermentation collaboration to add revenue.
- →FY27 EBITDA for capsules expected to improve given product mix shift and optimizing plant utilization.
- →Overall profitability at consolidated level aimed to be restored in FY27, after losses in FY26 driven by API pre-commercial costs and plant disruptions.
- →EPS and net profits expected to improve as revenue scale-up from HPMC and API segments materialize over next 2-3 years.
3 more insights locked — sign up free to unlock
Fundraise plans
- →Natural Capsules is exploring various fundraising options due to ongoing liquidity pressures.
- →They have applied for government funding under the RDI scheme to BIRAC as a deep tech pharma API company.
- →The company expects to contribute an equal amount of funding from their side, potentially in the form of equity.
- →Preferential allotment involving promoters' participation and a rights issue are possibilities.
- →The promoter group currently does not intend to significantly dilute their overall holding.
- →There was no mention of immediate plans to raise debt, but discussions on fundraising options imply debt could be considered as part of overall strategy.
Order book
- →Natural Capsules currently has an order book with a backlog of approximately 36 days for all types of capsules.
- →The backlog indicates steady demand and ongoing business operations despite market challenges.
- →For the HPMC capsules segment, the company is aggressively working to get approvals, particularly in the US market, to start and expand business.
- →The order book demonstrates active market engagement, with dedicated teams managing gelatin and HPMC capsules.
- →No explicit mention of pending orders beyond the 36-day backlog is given, but the company's focus on increasing utilization and regulatory approvals suggests planned growth in pending and future orders.
Capex plans
- Additional investment of Rs. 25-30 crores planned to add and ready two more clean rooms for API manufacturing to achieve the Rs. 250 crore revenue target (Page 15).
- Basic infrastructure for clean rooms is already made; completion and commissioning remain (Page 15).
- Application submitted under government RDI scheme to BIRAC to seek funding as a deep tech pharma API company; expecting matched equity contribution, possibly via preferential allotment or rights issue (Page 7).
- Promoter group currently prefers minimal equity dilution (Page 7).
- Investment to complete fermentation block and related facilities to be utilized by Fermbox bio under contract manufacturing arrangement; no specific capex figure mentioned but expected to optimize fermentation plant utilization and revenue sharing (Page 24).
- Scaling up HPMC capsule manufacturing line for regulated markets with revenue expected from second half of FY27 (Page 7).
These strategic investments focus on scaling API and capsule capacities and regulatory certifications to access regulated markets.
How does Natural Capsules rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Natural Capsules
See full Pharmaceuticals & Biotechnology sector rankings
How does Natural Capsules rank in Pharmaceuticals & Biotechnology?
Compare Natural Capsules against every Pharmaceuticals & Biotechnology company (Q4 FY26) on revenue, margins and earnings-call signals.